ALK and non-small cell lung carcinoma: In the treatment of NSCLC, successful application of EGFR and anaplastic lymphoma kinase (ALK)/met proto-oncogene tyrosine kinase inhibitors highlights the importance of genotype-based individualized targeted therapies [10–12].